Literature DB >> 32350203

Antithrombotic Therapy of a Young Adult with Giant Left Main Coronary Artery Aneurysm.

Tingting Chen1, Jing Li1, Qing Xu1, Xiaoyu Li1, Qianzhou Lv1, Hongyi Wu2.   

Abstract

Giant coronary artery aneurysm (CAA) is a rare disorder, defined as coronary artery dilatation, in which the diameter of the coronary artery exceeds more than 1.5 times of its normal size. The most common cause of CAA is coronary atherosclerosis for adults and Kawasaki disease (KD) for children and adolescents (especially for the giant CAA that occurred in adolescence). CAA complications include thrombus, acute myocardial infarction (AMI), vasospasm, rupture, ischemia, heart failure, and arrhythmia. So, antithrombotic therapy is crucial for patients with giant CAA.Although giant CAA has been reported in some cases before, few of these cases described antithrombotic therapy particularly, let alone informed direct oral anticoagulant (DOAC) use in these patients. Here, we report a case of a young patient with acute coronary artery disease caused by huge CAA. Rivaroxaban combined with clopidogrel was used for his antithrombotic therapy. Moreover, we reviewed the existing reports to provide an overview of antithrombotic treatment in patients with giant CAA.

Entities:  

Keywords:  Coronary angiography; Direct oral anticoagulants; Embolization; Rivaroxaban

Year:  2020        PMID: 32350203     DOI: 10.1536/ihj.19-451

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  2 in total

1.  Thromboembolic ST elevation myocardial infarction due to a large coronary aneurysm: Role of apixaban.

Authors:  Stefania Cherubini; Alessandro Sciahbasi; Maria Cera; Silvio Fedele; Giuseppe Ferraiuolo; Andrea Ciolli
Journal:  Anatol J Cardiol       Date:  2021-12       Impact factor: 1.596

2.  Coronary artery aneurysms caused by Kawasaki disease in an adult: A case report and literature review.

Authors:  Ying He; Hao Ji; Jian-Chang Xie; Liang Zhou
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.